News 2025-02-28
Porton to Showcase Cutting-edge Innovations at BIO-Europe Spring 2025
Porton Pharma Solutions will once again participate
in BIO-Europe Spring 2025, held from March 17th to 19th, at booth #87. This
prestigious event is anticipated to gather over 3,700 scientific leaders and
industry pioneers, fostering new strategic collaborations.
As a globally leading end-to-end CDMO enterprise, Porton Pharma Solutions stands at the forefront of the industry with its cutting-edge technology platforms and extensive project delivery experience. We excel in various fields, including small molecules, peptides and oligonucleotides, antibody-drug conjugates (ADCs) - encompassing antibodies, payload-linkers, conjugation, and formulation filling - as well as Advanced Therapy Medicinal Products (ATMPs).
At this conference, Porton will showcase its latest innovative solutions, aiming to provide you with flexible and diverse collaboration options that cater to your customized needs while driving continuous progress in the biopharmaceutical industry.
We cordially invite you to visit our booth #87 to discuss potential collaboration opportunities.
To ensure a more professional meeting experience for you, we have specially opened a booking channel. To schedule an onsite meeting, please visit our official website's offline meeting page, or directly email us at business@portonpharma.com. Our dedicated team will be more than happy to arrange your meeting and ensure your participation is both efficient and enjoyable.
Join us in exploring the future of pharmaceutical innovation at BIO-Europe Spring 2025!
Others
More
News 2026-10-24
Porton Shared Complex Bioconjugate Development Strategies at the 17th World ADC San Diego
As a conference partner, Porton contributed a scientific presentation and poster addressing the technical challenges of developing ADCs and emerging bioconjugates.

News 2026-10-22
Simplifying Synthesis with Radical Cross-Coupling: Prof. Phil S. Baran of Scripps Research Lectures at Porton
The event was hosted by Dr. Yongli Zhong, CSO, and attended by Mr. Oliver Ju, Chairman and CEO; Mr. Yunxing Yin, VP and Head of the Small Molecule Platform, and more than 200 R&D and technical staff.